MiLaboratories

Executive Summary

MiLaboratories, a Barcelona-based biotechnology company founded in 2015, specializes in computational solutions for adaptive immunity research. Its flagship platform, VDJ.online, enables deep analysis of immune receptor repertoires from T-cells and B-cells, providing critical insights for immunology and genomics studies. The platform is widely used by academic and pharmaceutical researchers to decode immune diversity, identify biomarkers, and advance immunotherapies. Despite operating in a competitive landscape with players like ImmunoMind and 10x Genomics, MiLaboratories differentiates itself through its user-friendly, cloud-based interface and focus on accessibility for non-bioinformaticians. The company has not disclosed funding rounds or revenue, but its steady growth and adoption in the scientific community suggest strong product-market fit. With the increasing importance of personalized medicine and immune-oncology, MiLaboratories is well-positioned to capture a growing share of the immune repertoire analysis market. Looking ahead, MiLaboratories is expected to leverage its technology for broader applications, including infectious disease monitoring and autoimmune disorder research. The company's lean operations and focused product strategy have enabled it to achieve profitability or near-profitability, though financial details remain private. Strategic partnerships with pharmaceutical companies or contract research organizations could accelerate adoption, while potential expansion into multi-omics integration would further differentiate its offerings. As the field of adaptive immunity continues to expand, MiLaboratories' platform serves as an essential tool for researchers, and the company is poised for sustained growth in the coming years.

Upcoming Catalysts (preview)

• Q3 2026Release of VDJ.online major update with enhanced multi-omics integration70% success
• 2026Strategic partnership with a top-10 pharmaceutical company for immune repertoire analysis50% success
• Q4 2026Series A funding round led by prominent health-tech VC80% success